CN113413408A - A Chinese medicinal capsule with anti-tumor effect, and its preparation method - Google Patents
A Chinese medicinal capsule with anti-tumor effect, and its preparation method Download PDFInfo
- Publication number
- CN113413408A CN113413408A CN202110806263.1A CN202110806263A CN113413408A CN 113413408 A CN113413408 A CN 113413408A CN 202110806263 A CN202110806263 A CN 202110806263A CN 113413408 A CN113413408 A CN 113413408A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- capsule
- tumor effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 36
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 47
- 239000000284 extract Substances 0.000 claims abstract description 32
- 239000008367 deionised water Substances 0.000 claims abstract description 26
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 239000012744 reinforcing agent Substances 0.000 claims abstract description 20
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 12
- 239000000661 sodium alginate Substances 0.000 claims abstract description 12
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 12
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 11
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 11
- 239000003623 enhancer Substances 0.000 claims abstract description 10
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 7
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 7
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 7
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 7
- 235000006533 astragalus Nutrition 0.000 claims abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 60
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 26
- 239000003054 catalyst Substances 0.000 claims description 25
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 claims description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000004473 Threonine Substances 0.000 claims description 13
- 229960002898 threonine Drugs 0.000 claims description 13
- 229940100684 pentylamine Drugs 0.000 claims description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 10
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 241000382455 Angelica sinensis Species 0.000 claims description 3
- 241000045403 Astragalus propinquus Species 0.000 claims description 3
- 239000012856 weighed raw material Substances 0.000 claims 1
- 241001061264 Astragalus Species 0.000 abstract description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 210000004233 talus Anatomy 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 150000001783 ceramides Chemical class 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000125175 Angelica Species 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- HYJVYOWKYPNSTK-UONOGXRCSA-N (2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoic acid Chemical compound N([C@H]([C@@H](O)C(O)=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 HYJVYOWKYPNSTK-UONOGXRCSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- LCZVKKUAUWQDPX-UHFFFAOYSA-N tert-butyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CC(=O)OC1=CC=CC=C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1=CC=CC=C1OC(C)=O LCZVKKUAUWQDPX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine capsule with an anti-tumor effect and a preparation method thereof, belonging to the technical field of anti-tumor traditional Chinese medicines, and the traditional Chinese medicine capsule with the anti-tumor effect comprises the following raw materials in parts by weight: 30-40 parts of traditional Chinese medicine extract, 20-30 parts of sodium alginate, 5-8 parts of reinforcing agent and 20-40 parts of deionized water, and the preparation steps comprise mixing, granulating, drying and the like; the traditional Chinese medicine extract is prepared from traditional Chinese medicinal materials with excellent anti-tumor activity, such as astragalus, purple sweater, pseudo-ginseng, angelica, gynostemma pentaphylla and poria cocos, and an enhancer is added during preparation, so that the traditional Chinese medicine extract has the activity of paclitaxel and the activity of ceramide analogues, not only has excellent anti-tumor activity, but also can enable active ingredients in the capsule to be in better contact with tumor cells and play a role.
Description
Technical Field
The invention relates to the technical field of anti-tumor traditional Chinese medicines, in particular to a traditional Chinese medicine capsule with an anti-tumor effect and a preparation method thereof.
Background
Tumor refers to a new organism formed by local tissue cell proliferation under the action of various tumorigenic factors, because the new organism mostly presents space-occupying block-shaped protrusions, which is also called neoplasm. According to the cellular characteristics of the new organism and the degree of harm to the organism, tumors are divided into two major categories, namely benign tumors and malignant tumors. The harm of tumor to human body is very large, most of which will affect human life, so it is necessary to prevent tumor.
The traditional Chinese medicine has many active ingredients, wherein the active ingredients have the effect of preventing tumors, the traditional Chinese medicine is natural in source and is not synthesized artificially, but the traditional Chinese medicine is mainly decocted and eaten, so that the traditional Chinese medicine is inconvenient to carry and eat, and a traditional Chinese medicine capsule needs to be prepared to solve the problem.
Disclosure of Invention
The purpose of the invention can be realized by the following technical scheme:
a traditional Chinese medicine capsule with an anti-tumor effect comprises the following raw materials in parts by weight: 30-40 parts of traditional Chinese medicine extract, 20-30 parts of sodium alginate, 5-8 parts of reinforcing agent and 20-40 parts of deionized water;
further, the traditional Chinese medicine extract is prepared by the following steps:
step A1: weighing the following raw materials in parts by weight: 5-8 parts of astragalus membranaceus, 2-4 parts of purple sweater, 1-2 parts of pseudo-ginseng, 1-3 parts of angelica sinensis, 1-3 parts of gynostemma pentaphylla and 1-3 parts of poria cocos;
step A2: crushing the raw materials weighed in the step A1, then placing the crushed raw materials in a pressure extraction tank, adding deionized water with the mass being 20 times that of the crushed raw materials, sealing the pressure extraction tank, and extracting the mixture for 2 hours at the pressure of 0.5Mpa and the temperature of 110 ℃; filtering the extractive solution with gauze, cooling, concentrating with rotary evaporator, and making into Chinese medicinal extract.
Further, the reinforcing agent is prepared by the following steps:
step S1: adding L-threonine and di-tert-butyl carbonate into a flask filled with deionized water and dioxane, and reacting for 1h at the temperature of 10-20 ℃ to obtain an intermediate 1; the dosage ratio of the L-threonine to the di-tert-butyl carbonate to the deionized water to the dioxane is 0.1 mol: 0.12 mol: 50mL of: 60 mL;
the reaction process is as follows:
step S2: adding the intermediate 1, pentylamine and dimethyl sulfoxide into a flask, adding a catalyst, and reacting at room temperature for 2h to obtain an intermediate 2; the dosage ratio of the intermediate 1, the pentylamine, the dimethyl sulfoxide and the catalyst is 0.1 mol: 0.11 mol: 20mL of: 0.5g, the catalyst is EDCI/HOBt with a molar ratio of 1: 1;
the reaction process is as follows:
step S3: adding the intermediate 2 into a flask filled with dichloromethane, dropwise adding trifluoroacetic acid into the flask by using a dropping funnel, stirring at room temperature for reacting for 2 hours, and performing rotary evaporation to obtain an intermediate 3; the using ratio of the intermediate 2, dichloromethane and trifluoroacetic acid is 1 mmol: 4mL of: 1 mL;
the reaction process is as follows:
step S4: adding the intermediate 3 and dichloromethane into a flask, then adding a paclitaxel side chain, adding a catalyst EDCI/HOBt with a molar ratio of 1:1, and reacting for 4 hours at room temperature to prepare an enhancer; the dosage ratio of the intermediate 3, dichloromethane, paclitaxel side chain and catalyst is 2 mmol: 10mL of: 2 mmol: 2 mmol.
A method for preparing Chinese medicinal capsule with anti-tumor effect comprises: the method comprises the following steps:
the method comprises the following steps: adding sodium alginate and deionized water into a beaker at 50 deg.C, stirring for 30min, adding the Chinese medicinal extract and the reinforcing agent into the beaker, and stirring for 30-50min to obtain a binding solution;
step two: and transferring the combined solution into an injector, slowly dripping the combined solution into sufficient calcium chloride solution with the mass fraction of 2% by using the injector at a constant speed, standing for 10min after dripping is finished, filtering, and drying the obtained wet capsule in a drying oven at 40 ℃ to obtain the traditional Chinese medicine capsule with the anti-tumor effect.
The invention provides a traditional Chinese medicine capsule with an anti-tumor effect and a preparation method thereof. Compared with the prior art, the method has the following beneficial effects:
1. according to the invention, astragalus, purple sweater, pseudo-ginseng, angelica, gynostemma pentaphylla, poria cocos and the like are used as base materials of traditional Chinese medicine extracts, the traditional Chinese medicine extracts are natural in source and non-toxic and have various effective components with anti-tumor activity, the traditional Chinese medicine extracts are extracted under pressure, the anti-tumor active components are extracted and concentrated to obtain traditional Chinese medicine extracts, and then the traditional Chinese medicine extracts and reinforcing agents are wrapped by sodium alginate to prepare microcapsules, so that the preparation of traditional Chinese medicine capsules is completed;
2. the invention has prepared a kind of intensifier, regard L-threonine as raw materials, protect amino of L-threonine at first with carbonic anhydride di-tert-butyl ester, then carboxyl and amino reaction of pentylamine of L-threonine, make intermediate 2, then deprotect intermediate 2, make its active amino expose, prepare and get intermediate 3, for the analog of ceramide, and then react with carboxyl of the taxol side chain with excellent antineoplastic activity to make intensifier, wherein because ceramide plays an important role in regulating cell growth and death, therefore ceramide metabolism and signal path are regarded as the potential target of anticancer therapy, make the ceramide analog have the same characteristic too, apply to the invention again, make the active material in the microcapsule of the invention can contact with tumor cell better and carry on the antitumor function, has the effect of enhancing the efficiency.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Preparing a reinforcing agent, wherein the reinforcing agent is prepared by the following steps:
step S1: adding L-threonine and di-tert-butyl carbonate into a flask filled with deionized water and dioxane, and reacting for 1h at the temperature of 10 ℃ to obtain an intermediate 1; the dosage ratio of the L-threonine to the di-tert-butyl carbonate to the deionized water to the dioxane is 0.1 mol: 0.12 mol: 50mL of: 60 mL;
step S2: adding the intermediate 1, pentylamine and dimethyl sulfoxide into a flask, adding a catalyst, and reacting at room temperature for 2h to obtain an intermediate 2; the dosage ratio of the intermediate 1, the pentylamine, the dimethyl sulfoxide and the catalyst is 0.1 mol: 0.11 mol: 20mL of: 0.5g, the catalyst is EDCI/HOBt with a molar ratio of 1: 1;
step S3: adding the intermediate 2 into a flask filled with dichloromethane, dropwise adding trifluoroacetic acid into the flask by using a dropping funnel, stirring at room temperature for reacting for 2 hours, and performing rotary evaporation to obtain an intermediate 3; the using ratio of the intermediate 2, dichloromethane and trifluoroacetic acid is 1 mmol: 4mL of: 1 mL;
step S4: adding the intermediate 3 and dichloromethane into a flask, then adding a paclitaxel side chain, adding a catalyst EDCI/HOBt with a molar ratio of 1:1, and reacting for 4 hours at room temperature to prepare an enhancer; the dosage ratio of the intermediate 3, dichloromethane, paclitaxel side chain and catalyst is 2 mmol: 10mL of: 2 mmol: 2 mmol.
Example 2
Preparing a reinforcing agent, wherein the reinforcing agent is prepared by the following steps:
step S1: adding L-threonine and di-tert-butyl carbonate into a flask filled with deionized water and dioxane, and reacting for 1h at the temperature of 15 ℃ to obtain an intermediate 1; the dosage ratio of the L-threonine to the di-tert-butyl carbonate to the deionized water to the dioxane is 0.1 mol: 0.12 mol: 50mL of: 60 mL;
step S2: adding the intermediate 1, pentylamine and dimethyl sulfoxide into a flask, adding a catalyst, and reacting at room temperature for 2h to obtain an intermediate 2; the dosage ratio of the intermediate 1, the pentylamine, the dimethyl sulfoxide and the catalyst is 0.1 mol: 0.11 mol: 20mL of: 0.5g, the catalyst is EDCI/HOBt with a molar ratio of 1: 1;
step S3: adding the intermediate 2 into a flask filled with dichloromethane, dropwise adding trifluoroacetic acid into the flask by using a dropping funnel, stirring at room temperature for reacting for 2 hours, and performing rotary evaporation to obtain an intermediate 3; the using ratio of the intermediate 2, dichloromethane and trifluoroacetic acid is 1 mmol: 4mL of: 1 mL;
step S4: adding the intermediate 3 and dichloromethane into a flask, then adding a paclitaxel side chain, adding a catalyst EDCI/HOBt with a molar ratio of 1:1, and reacting for 4 hours at room temperature to prepare an enhancer; the dosage ratio of the intermediate 3, dichloromethane, paclitaxel side chain and catalyst is 2 mmol: 10mL of: 2 mmol: 2 mmol.
Example 3
Preparing a reinforcing agent, wherein the reinforcing agent is prepared by the following steps:
step S1: adding L-threonine and di-tert-butyl carbonate into a flask filled with deionized water and dioxane, and reacting for 1h at the temperature of 20 ℃ to obtain an intermediate 1; the dosage ratio of the L-threonine to the di-tert-butyl carbonate to the deionized water to the dioxane is 0.1 mol: 0.12 mol: 50mL of: 60 mL;
step S2: adding the intermediate 1, pentylamine and dimethyl sulfoxide into a flask, adding a catalyst, and reacting at room temperature for 2h to obtain an intermediate 2; the dosage ratio of the intermediate 1, the pentylamine, the dimethyl sulfoxide and the catalyst is 0.1 mol: 0.11 mol: 20mL of: 0.5g, the catalyst is EDCI/HOBt with a molar ratio of 1: 1;
step S3: adding the intermediate 2 into a flask filled with dichloromethane, dropwise adding trifluoroacetic acid into the flask by using a dropping funnel, stirring at room temperature for reacting for 2 hours, and performing rotary evaporation to obtain an intermediate 3; the using ratio of the intermediate 2, dichloromethane and trifluoroacetic acid is 1 mmol: 4mL of: 1 mL;
step S4: adding the intermediate 3 and dichloromethane into a flask, then adding a paclitaxel side chain, adding a catalyst EDCI/HOBt with a molar ratio of 1:1, and reacting for 4 hours at room temperature to prepare an enhancer; the dosage ratio of the intermediate 3, dichloromethane, paclitaxel side chain and catalyst is 2 mmol: 10mL of: 2 mmol: 2 mmol.
Example 4
Preparing a traditional Chinese medicine extract, wherein the traditional Chinese medicine extract is prepared by the following steps:
step A1: weighing the following raw materials in parts by weight: 5 parts of astragalus membranaceus, 2 parts of purple sweater, 1 part of pseudo-ginseng, 1 part of angelica sinensis, 1 part of gynostemma pentaphylla and 1 part of poria cocos;
step A2: crushing the raw materials weighed in the step A1, then placing the crushed raw materials in a pressure extraction tank, adding deionized water with the mass being 20 times that of the crushed raw materials, sealing the pressure extraction tank, and extracting the mixture for 2 hours at the pressure of 0.5Mpa and the temperature of 110 ℃; filtering the extractive solution with gauze, cooling, concentrating with rotary evaporator, and making into Chinese medicinal extract.
Example 5
Preparing a traditional Chinese medicine extract, wherein the traditional Chinese medicine extract is prepared by the following steps:
step A1: weighing the following raw materials in parts by weight: 6.5 parts of astragalus, 3 parts of purple sweater, 1.5 parts of pseudo-ginseng, 2 parts of angelica, 2 parts of gynostemma pentaphylla and 2 parts of poria cocos;
step A2: crushing the raw materials weighed in the step A1, then placing the crushed raw materials in a pressure extraction tank, adding deionized water with the mass being 20 times that of the crushed raw materials, sealing the pressure extraction tank, and extracting the mixture for 2 hours at the pressure of 0.5Mpa and the temperature of 110 ℃; filtering the extractive solution with gauze, cooling, concentrating with rotary evaporator, and making into Chinese medicinal extract.
Example 6
Preparing a traditional Chinese medicine extract, wherein the traditional Chinese medicine extract is prepared by the following steps:
step A1: weighing the following raw materials in parts by weight: 8 parts of astragalus, 4 parts of purple sweater, 2 parts of pseudo-ginseng, 3 parts of angelica, 3 parts of gynostemma pentaphylla and 3 parts of poria cocos;
step A2: crushing the raw materials weighed in the step A1, then placing the crushed raw materials in a pressure extraction tank, adding deionized water with the mass being 20 times that of the crushed raw materials, sealing the pressure extraction tank, and extracting the mixture for 2 hours at the pressure of 0.5Mpa and the temperature of 110 ℃; filtering the extractive solution with gauze, cooling, concentrating with rotary evaporator, and making into Chinese medicinal extract.
Example 7
A traditional Chinese medicine capsule with an anti-tumor effect comprises the following raw materials in parts by weight: 30 parts of traditional Chinese medicine extract, 20 parts of sodium alginate, 5 parts of reinforcing agent and 20 parts of deionized water;
the preparation method of the traditional Chinese medicine capsule with the anti-tumor effect comprises the following steps: the method comprises the following steps:
the method comprises the following steps: adding sodium alginate and deionized water into a beaker at 50 deg.C, stirring for 30min, adding the Chinese medicinal extract and the reinforcing agent into the beaker, and stirring for 30min to obtain a binding solution;
step two: and transferring the combined solution into an injector, slowly dripping the combined solution into sufficient calcium chloride solution with the mass fraction of 2% by using the injector at a constant speed, standing for 10min after dripping is finished, filtering, and drying the obtained wet capsule in a drying oven at 40 ℃ to obtain the traditional Chinese medicine capsule with the anti-tumor effect.
Example 8
A traditional Chinese medicine capsule with an anti-tumor effect comprises the following raw materials in parts by weight: 35 parts of traditional Chinese medicine extract, 25 parts of sodium alginate, 6.5 parts of reinforcing agent and 30 parts of deionized water;
the preparation method of the traditional Chinese medicine capsule with the anti-tumor effect comprises the following steps: the method comprises the following steps:
the method comprises the following steps: adding sodium alginate and deionized water into a beaker at 50 deg.C, stirring for 30min, adding the Chinese medicinal extract and the reinforcing agent into the beaker, and stirring for 40min to obtain a binding solution;
step two: and transferring the combined solution into an injector, slowly dripping the combined solution into sufficient calcium chloride solution with the mass fraction of 2% by using the injector at a constant speed, standing for 10min after dripping is finished, filtering, and drying the obtained wet capsule in a drying oven at 40 ℃ to obtain the traditional Chinese medicine capsule with the anti-tumor effect.
Example 9
A traditional Chinese medicine capsule with an anti-tumor effect comprises the following raw materials in parts by weight: 40 parts of traditional Chinese medicine extract, 30 parts of sodium alginate, 8 parts of reinforcing agent and 40 parts of deionized water;
the preparation method of the traditional Chinese medicine capsule with the anti-tumor effect comprises the following steps: the method comprises the following steps:
the method comprises the following steps: adding sodium alginate and deionized water into a beaker at 50 deg.C, stirring for 30min, adding the Chinese medicinal extract and the reinforcing agent into the beaker, and stirring for 50min to obtain a binding solution;
step two: and transferring the combined solution into an injector, slowly dripping the combined solution into sufficient calcium chloride solution with the mass fraction of 2% by using the injector at a constant speed, standing for 10min after dripping is finished, filtering, and drying the obtained wet capsule in a drying oven at 40 ℃ to obtain the traditional Chinese medicine capsule with the anti-tumor effect.
Comparative example 1: no enhancer was added compared to example 8.
Comparative example 2: compared with example 8, no herbal extract was added.
Comparative example 3: compared with example 8, no enhancer and herbal extract was added.
The performance tests of examples 7 to 9 and comparative examples 1 to 3 were performed, and the results obtained by performing cell experimental measurements using human liver cancer cells cultured to the logarithmic phase, detecting the inhibitory activity of cell sample proliferation using MTT, and comparing the inhibition rate indicators of liver cancer cells were as follows:
| experimental group | Inhibition ratio (%) |
| Example 7 | 34.6 |
| Example 8 | 35.1 |
| Example 9 | 35.0 |
| Comparative example 1 | 26.8 |
| Comparative example 2 | 11.2 |
| Comparative example 3 | Can not detect |
It can be seen from the above table that examples 7-9 have good anti-tumor activity, and the enhancer and the Chinese medicinal extract both have certain anti-tumor activity, and the enhancer plays a role in promoting the anti-tumor activity of the Chinese medicinal capsule.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. A traditional Chinese medicine capsule with an anti-tumor effect is characterized by comprising the following raw materials in parts by weight: 30-40 parts of traditional Chinese medicine extract, 20-30 parts of sodium alginate, 5-8 parts of reinforcing agent and 20-40 parts of deionized water;
the reinforcing agent is prepared by the following steps:
step S1: adding L-threonine and di-tert-butyl carbonate into a flask filled with deionized water and dioxane, and reacting for 1h at the temperature of 10-20 ℃ to obtain an intermediate 1;
step S2: adding the intermediate 1, pentylamine and dimethyl sulfoxide into a flask, adding a catalyst, and reacting at room temperature for 2h to obtain an intermediate 2;
step S3: adding the intermediate 2 into a flask filled with dichloromethane, dropwise adding trifluoroacetic acid into the flask by using a dropping funnel, stirring at room temperature for reacting for 2 hours, and performing rotary evaporation to obtain an intermediate 3;
step S4: adding the intermediate 3 and dichloromethane into a flask, adding a paclitaxel side chain, adding a catalyst EDCI/HOBt with a molar ratio of 1:1, and reacting at room temperature for 4h to obtain the enhancer.
2. The capsule of claim 1, wherein the dosage ratio of L-threonine, di-tert-butyl carbonate, deionized water and dioxane in step S1 is 0.1 mol: 0.12 mol: 50mL of: 60 mL.
3. The capsule of claim 1, wherein in step S2, the dosage ratio of the intermediate 1, pentylamine, dimethyl sulfoxide and catalyst is 0.1 mol: 0.11 mol: 20mL of: 0.5g, the catalyst is EDCI/HOBt with a molar ratio of 1: 1.
4. The capsule of claim 1, wherein the intermediate 2, dichloromethane and trifluoroacetic acid in step S3 are used in a ratio of 1 mmol: 4mL of: 1 mL.
5. The capsule of claim 1, wherein the ratio of the intermediate 3, dichloromethane, paclitaxel side chain, and catalyst in step S4 is 2 mmol: 10mL of: 2 mmol: 2 mmol.
6. The traditional Chinese medicine capsule with anti-tumor effect according to claim 1, characterized in that the traditional Chinese medicine extract is prepared by the following steps:
crushing the weighed raw materials, putting the crushed raw materials into a pressure extraction tank, adding deionized water with the mass of 20 times, sealing, and extracting for 2 hours at the pressure of 0.5Mpa and the temperature of 110 ℃; filtering the extractive solution with gauze, cooling, concentrating, and making into Chinese medicinal extract.
7. The traditional Chinese medicine capsule with the anti-tumor effect according to claim 6, which is characterized by comprising the following raw materials in parts by weight: 5-8 parts of astragalus membranaceus, 2-4 parts of purple sweater, 1-2 parts of pseudo-ginseng, 1-3 parts of angelica sinensis, 1-3 parts of gynostemma pentaphylla and 1-3 parts of poria cocos.
8. The preparation method of the traditional Chinese medicine capsule with the anti-tumor effect according to claim 1, which is characterized by comprising the following steps:
the method comprises the following steps: adding sodium alginate and deionized water into a beaker at 50 deg.C, stirring for 30min, adding the Chinese medicinal extract and the reinforcing agent into the beaker, and stirring for 30-50min to obtain a binding solution;
step two: transferring the combined solution into an injector, slowly dripping the combined solution into a calcium chloride solution with the mass fraction of 2% by using the injector at a constant speed, standing for 10min after dripping, filtering, and drying the obtained wet capsule in a drying oven at 40 ℃ to obtain the traditional Chinese medicine capsule with the anti-tumor effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110806263.1A CN113413408A (en) | 2021-07-16 | 2021-07-16 | A Chinese medicinal capsule with anti-tumor effect, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110806263.1A CN113413408A (en) | 2021-07-16 | 2021-07-16 | A Chinese medicinal capsule with anti-tumor effect, and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113413408A true CN113413408A (en) | 2021-09-21 |
Family
ID=77721305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110806263.1A Pending CN113413408A (en) | 2021-07-16 | 2021-07-16 | A Chinese medicinal capsule with anti-tumor effect, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113413408A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1302657A (en) * | 1999-10-29 | 2001-07-11 | 中国科学院上海细胞生物学研究所 | Medicine for induction-differential therapy and its application |
| CN1692917A (en) * | 2004-05-09 | 2005-11-09 | 北京奇源益德药物研究所 | Traditional Chinese medicine prepns. for anti-tumor and enhancing immunity, and its prepn. method |
| CN103340883A (en) * | 2013-07-25 | 2013-10-09 | 山东大学 | Ceramide-based combined medicine for treating tumor |
| CN104814989A (en) * | 2015-04-21 | 2015-08-05 | 四川联成迅康医药股份有限公司 | Drug combination for treating tumor |
| CN104825512A (en) * | 2015-04-21 | 2015-08-12 | 四川联成迅康医药股份有限公司 | Tumor treatment combination drug |
| CN111763179A (en) * | 2020-07-08 | 2020-10-13 | 云南汉德生物技术有限公司 | Synthesis method of paclitaxel side chain |
-
2021
- 2021-07-16 CN CN202110806263.1A patent/CN113413408A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1302657A (en) * | 1999-10-29 | 2001-07-11 | 中国科学院上海细胞生物学研究所 | Medicine for induction-differential therapy and its application |
| CN1692917A (en) * | 2004-05-09 | 2005-11-09 | 北京奇源益德药物研究所 | Traditional Chinese medicine prepns. for anti-tumor and enhancing immunity, and its prepn. method |
| CN103340883A (en) * | 2013-07-25 | 2013-10-09 | 山东大学 | Ceramide-based combined medicine for treating tumor |
| CN104814989A (en) * | 2015-04-21 | 2015-08-05 | 四川联成迅康医药股份有限公司 | Drug combination for treating tumor |
| CN104825512A (en) * | 2015-04-21 | 2015-08-12 | 四川联成迅康医药股份有限公司 | Tumor treatment combination drug |
| CN111763179A (en) * | 2020-07-08 | 2020-10-13 | 云南汉德生物技术有限公司 | Synthesis method of paclitaxel side chain |
Non-Patent Citations (3)
| Title |
|---|
| QIANQIAN LIU，等: "Chemical synthesis and functional characterization of a new class of ceramide analogues as anti-cancer agents", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
| 吴大真: "《战胜癌症，这些细节能救你的命》", 30 September 2017, 湖南科学技术出版 * |
| 盛家骏，等: "多组分反应合成紫杉醇侧链及其在合成紫杉醇衍生物中的应用", 《有机化学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108752302A (en) | The purposes of 2- (2- phenethyls) chromone compounds in agalloch eaglewood | |
| CN113413408A (en) | A Chinese medicinal capsule with anti-tumor effect, and its preparation method | |
| CN102875615B (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN112341370B (en) | Synthesis method and application of o-vanillin Schiff base platinum complex | |
| CN100415228C (en) | Medicine containing galangin and preparation method thereof | |
| CN108938677A (en) | A kind of Sargassum polycystum extract and the preparation method and application thereof with treatment breast cancer effect | |
| CN114805404A (en) | Metal complex based on dehydroabietylamine and preparation method and application thereof | |
| CN110787094B (en) | Application of Xingan worm extract in preparation of whitening cosmetics | |
| CN102988525A (en) | Preparation method for total lignans in hawthorn seeds, and novel application | |
| CN107540569B (en) | Laminarinic ester group bromo-oxamide derivative with anticancer activity and composition thereof | |
| CN108017608A (en) | Flavone derivatives and its preparation method and application | |
| CN111084791A (en) | Application of polyrhachis vicina Roger extract in preparation of medicines for preventing and treating breast cancer and related diseases | |
| CN101513398A (en) | Application of ginkgol in resisting tumors | |
| CN107362158B (en) | Application of loganin aglycone in preparation of antitumor drugs | |
| RU2425690C1 (en) | Method of preparing polyphenol agent from lady's mantle, capable of reducing toxicity of cyclophosphamide and having cytotoxic activity | |
| WO2004069263A1 (en) | Analgesic composition | |
| CN112545943B (en) | SOD cosmetic additive containing plant extract | |
| CN114292889B (en) | Preparation method and application of amorpha fruticosa flower polysaccharide | |
| CN115137776B (en) | Preparation method of Chinese medicinal composition containing red sage root, cape jasmine fruit and Chinese medicinal herb | |
| CN101289453A (en) | Ellagic acid compounds, preparation thereof and applications in anticancer drugs | |
| CN115040522B (en) | Medicine for treating lung cancer and preparation method thereof | |
| CN101347493B (en) | Use of shamrock extract in preparing anti-tumor medicament | |
| CN111544448A (en) | Anti-tumor composition and preparation method thereof | |
| CN111973701A (en) | Application of garlic-allium mongolicum regel composition in preparation of product for preventing and/or treating cancer | |
| RU2403055C1 (en) | Method of obtaining medication from herb of lady's mantle, which reduces cyclophosphamide toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210921 |
|
| RJ01 | Rejection of invention patent application after publication |